Hims & Hers Completes Acquisition of Apostrophe
07 Julho 2021 - 05:13PM
Business Wire
Combining Forces to Expand Hims & Hers’
Personalized Dermatology Offerings
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS),
the multi-specialty telehealth platform focused on providing modern
personalized health and wellness experiences to consumers, today
announced it has finalized the acquisition of teledermatology
specialist, Apostrophe. With this closing, Hims & Hers will
expand its ability to provide consumers with some of the most
advanced and personalized dermatology treatments, faster and at
scale.
“Today begins a new chapter of clearer, healthier skin for
consumers,” said Andrew Dudum, Chief Executive Officer and
co-founder of Hims & Hers. “The future of dermatology is in
providing highly personalized products that fit consumers’ needs.
With this acquisition, Hims & Hers gains a trusted partner with
expertise in charting this new future, as well as a leadership team
that will help take our dermatology business to the next level. We
are thrilled to be joining forces with the Apostrophe team and
working together to help more people access high quality,
personalized products to improve their skin through our
platform.”
As previously announced, the entire Apostrophe team, which
includes world-class dermatology experts, will be joining Hims
& Hers to help run the company’s growing dermatology business
line. Apostrophe Chief Executive Officer and Co-Founder Ben Holber
will become CEO of the Hims & Hers dermatology business line,
reporting directly to Hims & Hers Chief Operating Officer
Melissa Baird.
LionTree Advisors served as exclusive financial advisor and
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP
acted as legal advisor to Hims & Hers.
Intrepid Investment Bankers LLC acted as exclusive financial
advisor, and Venable LLP acted as legal advisor to Apostrophe.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements can be identified by the
use of forward-looking terminology, including the words “believes,”
“estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,”
“will,” “potential,” “projects,” “predicts,” “continue,” or
“should,” or, in each case, their negative or other variations or
comparable terminology. There can be no assurance that actual
results will not materially differ from expectations. Such
statements include, but are not limited to, any statements relating
to Hims & Hers’ expansion plans, and the anticipated impacts of
the transaction on Hims & Hers’ business. These statements are
based on management’s current expectations, but actual results may
differ materially due to various factors. By their nature,
forward-looking statements involve risks and uncertainties because
they relate to events and depend on circumstances that may or may
not occur in the future.
The forward-looking statements contained in this press release
are based on our current expectations and beliefs concerning future
developments and their potential effects on us. Future developments
affecting us may not be those that we have anticipated. These
forward-looking statements involve a number of risks, uncertainties
(some of which are beyond our control) and other assumptions that
may cause actual results or performance to be materially different
from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks associated with Apostrophe’s ongoing operations;
the possibility that the expected benefits of the acquisition are
not realized when expected or at all; Hims & Hers’ ability to
integrate the Apostrophe team into its business; and consumer
acceptance and changes in demand for Apostrophe’s and Hims &
Hers’ products, as well as those factors described in the “Risk
Factors” and other sections of Hims & Hers’ most recent Annual
Report on Form 10-K, most recent Quarterly Report on Form 10-Q and
other current and periodic reports we file from time to time with
the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize,
or should any of our assumptions prove incorrect, actual results
may vary in material respects from those projected in these
forward-looking statements. We undertake no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws.
About Hims & Hers
Hims & Hers is a multi-specialty telehealth platform that
connects consumers to licensed healthcare professionals, enabling
them to access high-quality medical care for numerous conditions
related to primary care, mental health, sexual health, dermatology,
and more. Launched in November 2017, the company also offers
thoughtfully created and curated health and wellness products. With
products and services available across all 50 states and
Washington, D.C., Hims & Hers is able to provide access to
quality, convenient and affordable care for all Americans. Hims
& Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack
Abraham and Joe Spector at venture studio Atomic in San Francisco,
California. For more information about Hims & Hers, please
visit forhims.com and forhers.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210707005827/en/
Linda O'Connor press@forhims.com
Hims and Hers Health (NYSE:HIMS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Hims and Hers Health (NYSE:HIMS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024